NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020
2019; National Comprehensive Cancer; Volume: 17; Issue: 12 Linguagem: Inglês
10.6004/jnccn.2019.0059
ISSN1540-1413
AutoresDavid S. Ettinger, Douglas E. Wood, Charu Aggarwal, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, Débora S. Bruno, Joe Y. Chang, Lucian R. Chirieac, Thomas A. D’Amico, Thomas J. Dilling, M.C. Dobelbower, Scott Gettinger, Ramaswamy Govindan, Matthew A. Gubens, Mark Hennon, Leora Horn, Rudy P. Lackner, Michael Lanuti, Ticiana Leal, Jules Lin, Billy W. Loo, Renato Martins, Gregory A. Otterson, Sandip Pravin Patel, Karen L. Reckamp, Gregory J. Riely, Steven E. Schild, Theresa A. Shapiro, James Stevenson, Scott J. Swanson, Kurt W. Tauer, Stephen C. Yang, Kristina M. Gregory, Miranda Hughes,
Tópico(s)Lung Cancer Diagnosis and Treatment
ResumoThe NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates in immunotherapy. For the 2020 update, all of the systemic therapy regimens have been categorized using a new preference stratification system; certain regimens are now recommended as "preferred interventions," whereas others are categorized as either "other recommended interventions" or "useful under certain circumstances."
Referência(s)